Recursion Pharmaceuticals (RXRX) Short term Debt (2023 - 2026)

Recursion Pharmaceuticals has reported Short term Debt for 4 years, with the latest figure at $9.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 7.9% year-over-year to $9.3 million; the trailing twelve-month figure through Mar 2026 stood at $9.3 million (up 7.9% YoY), and the FY2025 full-year result was $9.1 million, up 7.91% from the prior year.
• Short term Debt for Q1 2026 stood at $9.3 million, up from $9.1 million in the prior quarter.
• The five-year high for Short term Debt was $9.3 million in Q1 2026, with the low at $41000.0 in Q4 2023.
• Historically, Short term Debt has averaged $7.7 million across 4 years, with a median of $8.6 million in 2025.
• Annual changes were most pronounced in 2024 — Short term Debt surged 20448.78% — and 2026, when it rose 7.9%.
• Recursion Pharmaceuticals' Short term Debt stood at $41000.0 in 2023, then surged by 20448.78% to $8.4 million in 2024, then advanced by 7.91% to $9.1 million in 2025, then advanced by 1.91% to $9.3 million in 2026.
• The last three Short term Debt figures came in at $9.3 million (Q1 2026), $9.1 million (Q4 2025), and $8.9 million (Q3 2025), per Business Quant data.